Profile picture
, 3 tweets, 2 min read
My Authors
Read all threads
Just out @nature: 35% of healthy people (#SARSCoV2 seronegative) have reactive SARSCoV2 CD4 T cells to spike protein, presumably d/t cross-reactive coronavirus exposure
nature.com/articles/s4158…
Important implications for explaining variable response to infections & vaccine trials
The healthy people in this report were an average age of 42, youngest age 20. Wondering what per cent in kids with ready made CD4 T cells vs #SARSCoV2 (likely higher than 35%)
The healthy people SARSCoV2 seronegative and their T cell reactive response (RHD) to the 4 common cold coronaviruses
(from supplementary material).
Extends prior work @CellCellPress cell.com/cell/pdf/S0092…
Missing some Tweet in this thread? You can try to force a refresh.

Keep Current with Eric Topol

Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

Twitter may remove this content at anytime, convert it as a PDF, save and print for later use!

Try unrolling a thread yourself!

how to unroll video

1) Follow Thread Reader App on Twitter so you can easily mention us!

2) Go to a Twitter thread (series of Tweets by the same owner) and mention us with a keyword "unroll" @threadreaderapp unroll

You can practice here first or read more on our help page!

Related hashtags

#SARSCoV2

More from @EricTopol see all

Profile picture
Eric Topol
@EricTopol
The time to move to rapid #SARSCoV2 testing is long overdue. It's about switching from diagnosing *infections* to determining whether someone is *infectious*
In minutes, not days. Anywhere. Cheap.
My table here summarizes the differences and why this should be the #1 US priority
In order to get this done, we need a reboot at @US_FDA, which currently requires rapid tests to perform like PCR tests.

That's wrong. This is a new diagnostic category for the *infectious* endpoint, requiring new standards and prospective validation.
The @US_FDA just came around today (yes, a new template, a coincidence with the prior post). Great to see a sign of progress
fda.gov/news-events/pr… via @nataliexdean @DanLarremore
Read 3 tweets
Profile picture
Eric Topol
@EricTopol
This simple #SARSCoV2 saliva test costs $1, gets results in <1 hour, and can be performed anywhere without electricity
medrxiv.org/content/10.110… by @PrakashLab
Why isn't there US support to get rapid validation of such tests and provided to every household?
For a very good review of all the better types of tests in the hopper
cell.com/matter/pdf/S25…
Here's another excellent view of the landscape of the rapid tests
nature.com/articles/d4158…
Read 4 tweets
Profile picture
Eric Topol
@EricTopol
1. The early use of inhaled interferons is emerging as a promising strategy to prevent severe #COVID19: lines of support include mechanism, rare genomic variants, a multicenter retrospective report, and a small randomized trial
2. On mechanism, our innate immune response, first line of defense relies, at least in part, on the interferon response.
2 figures from @VirusesImmunity's terrific thread, and the link to it
3. Yesterday's @JAMA_Current report of loss-of-function TRL7 rare variants in 4 young men from 2 independent families w/ severe #COVID19 connects with their impaired interferon response
Editorial @rplenge jamanetwork.com/journals/jama/…
Paper by @ahoischen et al jamanetwork.com/journals/jama/…
Read 8 tweets

Embed code for your website

×
Follow Us on Twitter!

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!